secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001641489-26-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026
--------------------------------------------------------------------------------

- Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.
- Cash and equivalents $88.9M at Dec 31, 2025, up from $36.7M; plus $20M non-dilutive from Newsoara in Feb 2026.
- Expect to complete enrollment in Phase 3 CATT1 trial for cadisegliatin in T1D in Q3 2026.
- R&D expenses rose to $17.9M in 2025 (2024: $11.5M) driven by higher cadisegliatin clinical spending.
- Amended Newsoara license grants global rights to PDE4 inhibitor HPP737 for $20M upfront plus up to $115M milestones and royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/0001641489-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/vtvt-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001641489-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer